Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137


HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort).

Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, Marcellin F, Esterle L, Wittkop L, Rosenthal E, Morlat P, Roux P, de Araujo WN, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

AIDS Behav. 2019 Jul 8. doi: 10.1007/s10461-019-02585-7. [Epub ahead of print]


Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).

Costa M, Rojas Rojas T, Lacoste D, Villes V, Aumaitre H, Protopopescu C, Yaya I, Wittkop L, Krause J, Salmon-Céron D, Marcellin F, Sogni P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]


No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).

Marcellin F, Protopopescu C, Wittkop L, Salmon-Ceron D, Sogni P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):274-276. doi: 10.1097/MEG.0000000000001301. No abstract available.


Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.

Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L, Roudot-Thoraval F; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups.

Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400. [Epub ahead of print]


Assessing the benefit of the 72-hour antibiotic therapy reassessment documentation.

Pérut V, Gauzit R, Kernéis S, Canouï E, Chedhomme FX, Batista R, Conort O, Bouam S, Raymond J, Loubinoux J, Chevallier A, Salmon-Ceron D.

Med Mal Infect. 2019 May;49(3):187-193. doi: 10.1016/j.medmal.2018.10.002. Epub 2018 Nov 9.


Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort).

Marcellin F, Costa M, Wittkop L, Protopopescu C, Esterle L, Salmon-Ceron D, Sogni P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Am J Gastroenterol. 2018 Nov;113(11):1729-1732. doi: 10.1038/s41395-018-0270-x. No abstract available.


Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.

Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, Dominguez S, Elegbe BA, Piroth L, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Jul 5;13(7):e0199874. doi: 10.1371/journal.pone.0199874. eCollection 2018.


Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.

Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Céron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups.

Liver Int. 2019 Jan;39(1):136-146. doi: 10.1111/liv.13921. Epub 2018 Jul 30.


Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort).

Yaya I, Marcellin F, Costa M, Morlat P, Protopopescu C, Pialoux G, Santos ME, Wittkop L, Esterle L, Gervais A, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13-HEPAVIH Cohort Study Group.

Nutrients. 2018 May 31;10(6). pii: E705. doi: 10.3390/nu10060705.


Reply to: "Coffee consumption and decreased all-cause mortality - What is the true estimate of effect?"

Protopopescu C, Marcellin F, Salmon-Ceron D, Carrieri MP.

J Hepatol. 2018 May;68(5):1106. doi: 10.1016/j.jhep.2018.01.032. Epub 2018 Feb 8. No abstract available.


Emergence of Lassa Fever Disease in Northern Togo: Report of Two Cases in Oti District in 2016.

Patassi AA, Landoh DE, Mebiny-Essoh Tchalla A, Halatoko WA, Assane H, Saka B, Naba MA, Yaya I, Edou KA, Tamekloe TA, Banla AK, Davi KM, Manga M, Kassankogno Y, Salmon-Ceron D.

Case Rep Infect Dis. 2017;2017:8242313. doi: 10.1155/2017/8242313. Epub 2017 Dec 17.


Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group.

HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7.


The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Wittkop L, Lacombe K, Esterle L, Sogni P, Salmon-Ceron D; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2018 Apr;68(4):845-847. doi: 10.1016/j.jhep.2017.10.025. Epub 2017 Nov 2. No abstract available.


Gender, Alcohol Use, and Fibrosis in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Individuals.

Yaya I, Costa M, Marcellin F, Miailhes P, Wittkop L, Salmon-Ceron D, Carrieri MP; Agence Nationale de Recherches sur le Sida et les Hépatites virales B et C (ANRS) CO13 HEPAVIH (hepatitis + VIH [= HIV in French]) Study Group.

Clin Infect Dis. 2018 Mar 5;66(6):983-984. doi: 10.1093/cid/cix927. No abstract available.


Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.

Marcellin F, Morlat P, Wittkop L, Salmon-Ceron D, Carrieri MP.

J Viral Hepat. 2018 Mar;25(3):314-315. doi: 10.1111/jvh.12811. Epub 2017 Nov 20. No abstract available.


Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).

Nordmann S, Vilotitch A, Roux P, Esterle L, Spire B, Marcellin F, Salmon-Ceron D, Dabis F, Chas J, Rey D, Wittkop L, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group.

J Viral Hepat. 2018 Feb;25(2):171-179. doi: 10.1111/jvh.12797. Epub 2017 Nov 20.


Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, Zucman D, Raffi F, Rosenthal E, Poizot-Martin I, Salmon-Ceron D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2017 Dec;67(6):1157-1167. doi: 10.1016/j.jhep.2017.08.005. Epub 2017 Sep 21.


Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort).

Yaya I, Roux P, Marcellin F, Salmon-Ceron D, Carrieri MP.

Dig Dis Sci. 2017 Oct;62(10):2943-2944. doi: 10.1007/s10620-017-4703-y. Epub 2017 Aug 5. No abstract available.


Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.

Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, Boué F, Rey D, Piroth L, Dominguez S, Sogni P, Salmon-Ceron D, Spire B, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Addiction. 2017 Sep;112(9):1669-1679. doi: 10.1111/add.13851. Epub 2017 Jun 6.


Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).

Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, Bouchaud O, Goujard C, Vittecoq D, Dabis F, Salmon-Ceron D, Spire B, Roux P, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):786-791. doi: 10.1097/MEG.0000000000000883.


Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.

Lacombe K, Fontaine H, Dhiver C, Metivier S, Rosenthal E, Antonini T, Valantin MA, Miailhes P, Harent S, Batisse D, Pageaux GP, Chas J, Aumaitre H, Dominguez S, Allegre T, Lafeuillade A, Billaud E, De Truchis P, Perre P, Leroy V, De Ledinghen V, Sogni P, Dabis F, Zhao Y, Filipovics A, Fedchuk L, Akremi R, Bennai Y, Salmon Ceron D.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):97-107. doi: 10.1097/QAI.0000000000001342.


Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences.

Patassi A, Benaboud S, Landoh DE, Salou M, Dagnra AC, Saka B, Krivine A, Meritet JF, Pitché P, Salmon-Ceron D.

S Afr Med J. 2016 May 10;106(6). doi: 10.7196/SAMJ.2016.v106i6.10312.


Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].

Michel L, Lions C, Winnock M, Lang JP, Loko MA, Rosenthal E, Marchou B, Valantin MA, Morlat P, Roux P, Sogni P, Spire B, Poizot-Martin I, Lacombe K, Lascoux-Combe C, Duvivier C, Neau D, Dabis F, Salmon-Ceron D, Carrieri MP; ANRS HEPAVIH CO13 study group.

HIV Med. 2016 Nov;17(10):758-765. doi: 10.1111/hiv.12382.


Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).

Marcellin F, Protopopescu C, Poizot-Martin I, Miailhes P, Esterle L, Wittkop L, Spire B, Bocquier A, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group.

Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1003-7. doi: 10.1097/MEG.0000000000000664.


No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).

Marcellin F, Lions C, Rosenthal E, Roux P, Sogni P, Wittkop L, Protopopescu C, Spire B, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group*.

Drug Alcohol Rev. 2017 Mar;36(2):227-238. doi: 10.1111/dar.12398. Epub 2016 Apr 13.


Detection and management of the first human anthrax outbreak in Togo.

Patassi AA, Saka B, Landoh DE, Agbenoko K, Tamekloe T, Salmon-Ceron D.

Trop Doct. 2016 Jul;46(3):129-34. doi: 10.1177/0049475515622331. Epub 2015 Dec 14.


[European Antibiotic Awareness Day: What is new in France?].

Pulcini C, Alfandari S, Ballereau F, Bonnet E, Bruneel F, Castan B, Chidiac C, Cohen R, Descamps D, Doco-Lecompte T, Gauzit R, Guéry B, Jarlier V, Lesprit P, Marcelin AG, Molina JM, Rabaud C, Riché A, Salmon-Céron D, Senneville E, Stahl JP, Tattevin P, Varon E, Roblot F; conseil d’administration de la SPILF.

Med Mal Infect. 2015 Sep;45(9):345-7. doi: 10.1016/j.medmal.2015.08.001. Epub 2015 Sep 26. French. No abstract available.


Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.

Lewin M, Gelu-Simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, Meyer L, Fontaine H, Salmon-Céron D, Samuel D, Seror O, Trinchet JC, Duclos-Vallée JC.

Radiology. 2015 Nov;277(2):443-53. doi: 10.1148/radiol.2015141500. Epub 2015 May 6.


Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group.

Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217. Epub 2015 Mar 16.


Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey.

Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P, Chêne G, Cacoub P; Mortalité 2010 and GERMIVIC study groups.

HIV Med. 2015 Apr;16(4):230-9. doi: 10.1111/hiv.12204. Epub 2014 Dec 18.


Vaccine knowledge in students in Paris, France, and surrounding regions.

Mellon G, Rigal L, Partouche H, Aoun O, Jaury P, Joannard N, Guthmann JP, Cochereau D, Caumes E, Bricaire F, Salmon-Céron D.

Can J Infect Dis Med Microbiol. 2014 May;25(3):141-6.


High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort.

Marcellin F, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, Salmon-Ceron D, Spire B, Carrieri MP; HEPAVIH (ANRS CO13) Study Group.

Clin Infect Dis. 2014 Oct 15;59(8):1190-2. doi: 10.1093/cid/ciu525. Epub 2014 Jul 11. No abstract available.


Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?

Gelu-Simeon M, Sobesky R, Haïm-Boukobza S, Ostos M, Teicher E, Fontaine H, Salmon-Ceron D, Meyer L, Trinchet JC, Paule B, Samuel D, Lewin M, Duclos-Vallée JC.

AIDS. 2014 Jun 19;28(10):1379-91. doi: 10.1097/QAD.0000000000000300. Review.


Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.

Marcellin F, Roux P, Winnock M, Lions C, Dabis F, Salmon-Ceron D, Loko MA, Spire B, Carrieri MP.

Expert Rev Gastroenterol Hepatol. 2014 May;8(4):351-8. doi: 10.1586/17474124.2014.888949. Epub 2014 Mar 3. Review.


Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.

Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH Study Group.

Antivir Ther. 2014;19(2):171-8. doi: 10.3851/IMP2699. Epub 2013 Oct 28.


Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.

Salmon-Ceron D, Arvieux C, Bourlière M, Cacoub P, Halfon P, Lacombe K, Pageaux GP, Pialoux G, Piroth L, Poizot-Martin I, Rosenthal E, Pol S; French Society of Infectious Diseases; French Association for the Study of the Liver; French AIDS Society; French Society of Internal Medicine.

Liver Int. 2014 Jul;34(6):869-89. doi: 10.1111/liv.12363. Epub 2013 Nov 25.


HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.

Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, Trimoulet P, Dabis F, Salmon-Ceron D, Izopet J; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289. Epub 2012 Nov 30.


Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).

Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group.

BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59.


A 26-year-old man presenting with loss of vision, skin lesions and wasting.

Chakvetadze C, Monfort JB, Dupin N, Carlotti A, Tan BK, Grange P, Guillevin L, Salmon-Ceron D.

Med Mal Infect. 2012 Feb;42(2):80-1. doi: 10.1016/j.medmal.2011.10.016. Epub 2012 Jan 28. No abstract available.


Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.

Serac G, Tubach F, Mariette X, Salmon-Céron D, Ravaud P, Lioté F, Laharie D, Ziza JM, Marguerie L, Bonnet C, Falgarone G, Nicolas N, Lortholary O, Chosidow O.

J Invest Dermatol. 2012 Mar;132(3 Pt 1):726-9. doi: 10.1038/jid.2011.383. Epub 2011 Nov 24. No abstract available.


Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.

Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chêne G; ANRS CO8 APROCO-COPILOTE Cohort Study Group.

AIDS. 2012 Jan 28;26(3):303-14. doi: 10.1097/QAD.0b013e32834e8776.


Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.

Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M.

J Hepatol. 2012 Mar;56(3):745-7. doi: 10.1016/j.jhep.2011.08.005. Epub 2011 Aug 31. No abstract available.


Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.

Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO-13-HEPAVIH Study Group.

Addiction. 2012 Jan;107(1):152-9. doi: 10.1111/j.1360-0443.2011.03608.x. Epub 2011 Oct 12.


Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician.

Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH study group.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):228-32. doi: 10.1016/j.drugalcdep.2010.09.025. Epub 2011 Jan 15.


Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X; RATIO group.

Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.


Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.

Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O; ANRS VAC18 trial group.

AIDS. 2010 Sep 10;24(14):2211-23. doi: 10.1097/QAD.0b013e32833ce566.


Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.

Burty C, Prazuck T, Truchetet F, Christian B, Penalba C, Salmon-Ceron D, Yazdanpanah Y, May T, Rabaud C.

AIDS Patient Care STDS. 2010 Jan;24(1):1-3. doi: 10.1089/apc.2009.0263. No abstract available.


Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008.

Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, Poizot-Martin I, Valantin MA, Bonnard P, Salmon-Céron D, Carrieri MP; ANRS Co13 HEPAVIH Study Group.

J Viral Hepat. 2010 Sep;17(9):650-60. doi: 10.1111/j.1365-2893.2009.01223.x. Epub 2009 Nov 11.


Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.

Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group.

Fundam Clin Pharmacol. 2009 Aug;23(4):491-500. doi: 10.1111/j.1472-8206.2009.00693.x.


Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, Barrou B, Duvivier C, Fontaine C, Welker Y, Billy C, de Truchis P, Delahousse M, Vittecoq D, Salmon-Céron D.

Am J Transplant. 2009 Aug;9(8):1946-52. doi: 10.1111/j.1600-6143.2009.02684.x. Epub 2009 Jun 10.

Supplemental Content

Loading ...
Support Center